On Thursday, Pfizer announced plans to advance its weight-loss pill after "encouraging" results from an early-stage study.  The pharmaceutical giant is trying to tap into the highly lucrative market for obesity drugs currently dominated by the likes of Eli Lilly and Novo Nordisk. HIMS & HERS ROLLS OUT WEIGHT-LOSS SHOTS MUCH CHEAPER THAN OZEMPIC, WEGOVY Pfizer said it has a "robust pipeline" of three clinical and several other pre-clinical candidates but that danuglipron, a once-a-day oral treatment, was "th ...

Eli Lilly logo is screened on a mobile phone for illustration photo. Krakow, Poland on April 9th, ... [+] 2024 (Photo by Beata Zawrzel/NurPhoto via Getty Images)NurPhoto via Getty ImagesWe believe that Eli Lilly stock (NYSE: LLY) is currently a better pick than its industry peer – Pfizer stock , given its better prospects. PFE stock trades at a much lower multiple of 2.8x revenues, versus 23.5x for LLY, and we think this gap in valuation will remain wide in favor of Eli Lilly. There is more to the compariso ...

ProArtWork Pfizer's (NYSE:PFE) cash flow from operations in 2022, driven by sales of the company's COVID-19 vaccine and Paxlovid, hit $29.267 billion. Fast-forward to 2023, and with COVID largely behind us, revenue from those products plummeted, pushing cash flow from operations down to $8.7 billion. With that in mind, it's not difficult to understand why the stock fell by roughly 23% over the last year. But there is more to Pfizer than coronavirus meds. The firm has a solid drug pipeline, and in an industr ...

Pfizer (PFE) closed the latest trading day at $27.93, indicating a -0.43% change from the previous session's end. The stock trailed the S&P 500, which registered a daily gain of 0.1%. At the same time, the Dow lost 0.08%, and the tech-heavy Nasdaq gained 0.28%.Prior to today's trading, shares of the drugmaker had lost 1.85% over the past month. This has lagged the Medical sector's loss of 0.44% and the S&P 500's gain of 4.08% in that time.Analysts and investors alike will be keeping a close eye on the perfo ...

Don't ignore this drugmaker simply because it's been unable to come up with a full replacement for Lipitor.Pfizer (PFE -0.20%) may not be the must-have pharmaceutical investment it was at one point. If your priority is reliable divided income, however, the drugmaker remains a rock-solid pick. Not only has it paid a dividend like clockwork for decades, the company has regularly raised its annual payout in recent years. Now that the dividend is well established, this streak isn't apt to end in the foreseeable ...

Shares of the world's largest drugmaker offer a dividend yield above 6% at recent prices.The past few years have been tough ones for investors holding shares of Pfizer (PFE 1.26%). The Big Pharma stock is down by more than half from the peak it set in late 2021.Pfizer's stock price was hammered, but that didn't prevent the company from meeting and raising its dividend commitment. Last December, the pharmaceutical company raised its payout for the 15th consecutive year.Shares of Pfizer offer an eye-popping 6 ...

Pfizer TodayPFEPfizer$28.22 +0.24 (+0.86%) 52-Week Range$25.20▼$37.80Dividend Yield5.95%Price Target$35.54Add to WatchlistPharmaceutical giant Pfizer Inc. NYSE: PFE has been trying to enter the weight-loss treatment trend dominated by GLP-1 drug makers like Ozempic and Wegovy makers Novo Nordisk A/S NYSE: NVO and Mounjaro and Zepbound makers Eli Lilly & Co. NYSE: LLY. Pfizer had failed in its previous attempts to create a viable GLP-1 contender. Pfizer operates in the medical sector. In addition to the incu ...

Pfizer's valuation looks attractive, but that doesn't mean the stock is a lock to outperform the broader market.Pfizer (PFE 0.86%) can be a polarizing stock to own right now. Its future remains hazy given that it is facing some troubling patent cliffs and revenue from its COVID-19 vaccine is dwindling. But at the same time, the shares look cheap, and they could possess a lot of upside in the long run. Investors, however, aren't exactly loading up on the stock. Year to date, it's down around 3%.The shares' t ...

Alexandros Michailidis In the last few years, I covered several pharmaceutical companies - including Gilead Sciences, Inc. (GILD), Novo Nordisk A/S (NVO) or Eli Lilly and Company (LLY) - and wrote in one way or another about many different pharmaceutical companies. But one major pharmaceutical company I never wrote about is Pfizer Inc. (NYSE:PFE). The company is one of the oldest and major pharmaceutical companies in the world and among the top 10 pharmaceutical companies (according to market capitalization ...

Pfizer Inc. (PFE) and BioNTech SE (BNTX) announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended marketing approval for their Omicron JN.1-adapted monovalent COVID-19 vaccine.The CHMP has recommended the approval of Comirnaty JN.1, the Omicron JN.1-adapted monovalent COVID-19 vaccine, for active immunization against the COVID-19 virus in individuals aged six months and above.The decision was based on the recommendation from the World Health ...